Abstract: COVID-19 - TOPICAL SUBJECT Science & Healthcare, 2021 (Vol. 23) 4 Received: 28 June 2021 / Accepted: 02 August 2021 / Published online: 31 August 2021 DOI 10.34689/SH.2021.23.4.001 UDC 616.40:615.7 CLINICAL EFFICACY OF THE ANTIVIRAL DRUG FAVIPIRAVIR IN THE COMPLEX TREATMENT OF PATIENTS WITH COVID-19 CORONAVIRUS INFECTION Sholpan A. Kulzhanova1, https://orcid.org/000-0002-4118-4905 Nurlan Е. Aukenov 2, https://orcid.org/0000-0002-3163-2997 Maiya E. Konkayeva1, https://orcid.org/0000-0002-1634-3855 Zauresh K. Smagulova1, Gulnara T. Tuleshova1, https://orcid.org/0000-0002-7309-5165 Saule B. Maukayeva3, http://orcid.org/ 0000-0002-2679-6399 Nazira Ye. Beisenbieva1, Gulsimzhan O. Turebaeva1, Gaukhar A. Nurakhmetova1, https://orcid.org/ 0000-0002-3279-9350 Aigul M. Utegenova1, https://orcid.org/ 0000-0002-5777-3747 1 NJSC “Astana Medical University”, Nur-Sultan, Republic of Kazakhstan; Ministry of Health of the Republic of Kazakhstan, Nur-Sultan, Republic of Kazakhstan; 3 NJSC “Semey Medical University”, Semey, Republic of Kazakhstan. 2 Abstract Introduction. It is known that most patients with COVID-19 have a disease of mild to moderate severity and can be treated at home. A potential etiotropic drug in the treatment of such patients is favipiravir. To finally decide on the inclusion of this drug in the international recommendations for the treatment of COVID-19, further studies are needed to assess its effectiveness and safety in patients with COVID-19. The aim of the study was to study the clinical efficacy of favipiravir in the complex therapy of patients with moderateseverity COVID-19 coronavirus infection. Materials and methods. A retrospective analysis of 468 medical records of an inpatient patient with a moderate form of coronavirus infection COVID-19, who were treated at the State Clinical Hospital at the Multi-Specialty Medical Center of the Akimat of Nur-Sultan, the Semey Infectious Diseases Hospital, for the period August-October 2020, was carried out. The experimental (main) group consisted of 40 patients with COVID-19 of moderate severity, who, in addition to standard therapy in accordance with the Clinical Protocol for Diagnosis and Treatment "COVID-19 Coronavirus infection (10th edition with changes from 15.07.2020), were prescribed oral favipiravir at a dose of 1600 mg/12 h on day 1, then 600 mg/12 h on the following days, for a total of 7 days. The comparison group (control group) consisted of 40 patients with moderate CVI who did not receive favipiravir. Descriptive statistics were performed with the calculation of the mean (M) and standard deviation (SD) for quantitative variables; percentages were calculated for qualitative variables. Statistical analysis was performed using Microsoft Excel and IBM SPSS Statistics 20.0. P <0.05 was considered statistically significant. Results and discussion. The present study showed that the early initiation of antiviral therapy with Favipiravir, compared with standard therapy without an antiviral drug, in patients with a moderate form of COVID-19 is associated with a statistically significant clinical improvement and a large percentage of virus elimination from the mucous membranes of the upper respiratory tract according to molecular genetic research. In the group of patients receiving favipiravir, complete remission of the disease with normalization of the main clinical parameters and the absence of complaints for 7 days of hospitalization was significantly more often than in..